Johnson Caroline H, Wilson Ian D, Harding John R, Stachulski Andrew V, Iddon Lisa, Nicholson Jeremy K, Lindon John C
Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of Medicine, Imperial College London, South Kensington, London SW7 2AZ, U.K.
Anal Chem. 2007 Nov 15;79(22):8720-7. doi: 10.1021/ac071368i. Epub 2007 Oct 18.
Carboxylic acid-containing drugs are often metabolized to 1-beta-O-acyl glucuronides (AGs). These can undergo an internal chemical rearrangement, and the resulting reactive positional isomers can bind to endogenous proteins, with clear potential for adverse effects. Additionally any 1-beta-O-acyl-glucuronidated phase I metabolite of the drug can also show this propensity, and investigation of the adverse effect potential of a drug also needs to consider such metabolites. Here the transacylation of the common drug ibuprofen and two of its metabolites is investigated in vitro. 1-beta-O-Acyl (S)-ibuprofen glucuronide was isolated from human urine and also synthesized by selective acylation. Urine was also used as a source of the (R)-ibuprofen, (S)-2-hydroxyibuprofen, and (S,S)-carboxyibuprofen AGs. The degradation rates (a combination of transacylation and hydrolysis) were measured using 1H NMR spectroscopy, and the measured decrease in the 1-beta anomer over time was used to derive half-lives for the glucuronides. The biosynthetic and chemically synthesized (S)-ibuprofen AGs had half-lives of 3.68 and 3.76 h, respectively. (R)-Ibuprofen AG had a half-life of 1.79 h, a value approximately half that of the (S)-diastereoisomer, consistent with results from other 2-aryl propionic acid drug AGs. The 2-hydroxyibuprofen and carboxyibuprofen AGs gave half-lives of 5.03 and 4.80 h, considerably longer than that of either of the parent drug glucuronides. In addition, two (S)-ibuprofen glucuronides were synthesized with the glucuronide carboxyl function esterified with either ethyl or allyl groups. The (S)-ibuprofen AG ethyl ester and (S)-ibuprofen AG allyl esters were determined to have half-lives of 7.24 and 9.35 h, respectively. In order to construct useful structure-reactivity relationships, it is necessary to evaluate transacylation and hydrolysis separately, and here it is shown that the (R)- and (S)-ibuprofen AGs have different transacylation properties. The implications of these findings are discussed in terms of structure-activity relationships.
含羧酸的药物通常会代谢为1-β-O-酰基葡萄糖醛酸苷(AGs)。这些物质可能会发生内部化学重排,生成的反应性位置异构体可与内源性蛋白质结合,具有明显的产生不良反应的可能性。此外,药物的任何1-β-O-酰基葡萄糖醛酸化的I相代谢物也可能表现出这种倾向,对药物不良反应可能性的研究也需要考虑此类代谢物。本文对常见药物布洛芬及其两种代谢物的转酰化反应进行了体外研究。从人尿中分离出1-β-O-酰基(S)-布洛芬葡萄糖醛酸苷,并通过选择性酰化反应进行合成。尿液还用作(R)-布洛芬、(S)-2-羟基布洛芬和(S,S)-羧基布洛芬AGs的来源。使用1H NMR光谱法测量降解速率(转酰化和水解的综合速率),并根据1-β异头物随时间的测量减少量得出葡萄糖醛酸苷的半衰期。生物合成的和化学合成的(S)-布洛芬AGs的半衰期分别为3.68小时和3.76小时。(R)-布洛芬AG的半衰期为1.79小时,约为(S)-非对映异构体半衰期的一半,这与其他2-芳基丙酸类药物AGs的结果一致。2-羟基布洛芬和羧基布洛芬AGs的半衰期分别为5.03小时和4.80小时,明显长于母体药物葡萄糖醛酸苷的半衰期。此外,合成了两种葡萄糖醛酸羧基功能分别被乙基或烯丙基酯化的(S)-布洛芬葡萄糖醛酸苷。(S)-布洛芬AG乙酯和(S)-布洛芬AG烯丙酯的半衰期分别测定为7.24小时和9.35小时。为了构建有用的结构-反应性关系,有必要分别评估转酰化和水解反应,本文表明(R)-和(S)-布洛芬AGs具有不同的转酰化性质。将根据结构-活性关系对这些发现的意义进行讨论。